EVAHEART®2 LVAS
Refractory NYHA Class IV Heart Failure (Bridge-to-Transplant or Destination Therapy)
Key Facts
About EvaHeart
EvaHeart is a private medical device company developing the EVAHEART®2 Left Ventricular Assist System, a novel LVAD designed to provide gentle, high-flow circulatory support while retaining physiological pulsatility. The company is currently conducting the COMPETENCE trial, a large-scale, randomized study comparing its device to the market-leading HeartMate 3, aiming for FDA approval in the US. With its technology already approved and used clinically in Japan since 2010, EvaHeart is positioning itself as a potential competitor in the global advanced heart failure device market by addressing key complications associated with traditional LVADs, such as pump thrombosis and bleeding events.
View full company profile